Intercept Statement Regarding Ocaliva Safety and Dosing in Primary Biliary Cholangitis (PBC) Patients, Says Patients Were Prescribed 7 Times Higher Than Weekly Recommended Doses; Intercept And FDA Issued Safety Communication To Reinforce Label Dosing